- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03380949
Monitor-Guided Analgesia During General Anesthesia - Part II (MOGADA-II)
Investigation of the Effect of Opioid Titration Guided by Analgesia Indices During Total Intravenous Anesthesia
Study Overview
Status
Conditions
Detailed Description
This prospective randomized clinical study aims to investigate the effects of a monitor-guided opioid analgesia during general anesthesia by different monitoring systems in comparison to routine clinical practice. Many surgical procedures require general anesthesia. The main components of general anesthesia are hypnosis and analgesia, and anesthesiologists usually combine a hypnotic drug with an opioid analgesic.
Until today, however, there is no standard-monitoring of nociception to specifically reflect the analgesic component of general anesthesia. In clinical practice the opioid dosage is chosen by clinical judgment of the attending anesthesiologist based upon changes of heart rate, blood pressure, pupil size, lacrimation and sweating of the patient.
On the one hand, underdosage of opioids can cause nociception leading to an increased sympathetic tone, increase of plasma levels of stress hormones, nociceptive movements as well as increase postoperative pain. On the other hand, overdosage of opioids can lead to drug side effects such as nausea and vomiting, hemodynamic instability, an increase in recovery times, immunosuppression and an increase in postoperative pain by opioid-induced-hyperalgesia. Quality and safety of general anesthesia are of major clinical importance and can be improved by limiting the administration of opioid analgesics to the optimal individual dose needed. In the last years, different analgesia monitoring devices have been developed for monitoring nociception. The present study evaluates the effects of the administration of opioids during general anesthesia guided by three different monitoring systems in comparison to routine clinical practice. All patients will receive general anesthesia with propofol guided by bispectral index (BIS) with a target of BIS values between 40 and 60. Opioid administration will be guided by one of three analgesic monitoring devices or the interpretation of clinical signs by the attending anesthesiologist in the control group. After institutional approval by the Ethics committee of the Medical Board of the City of Hamburg, Germany and obtaining patients' written informed consent we randomize elective patients with major abdominal surgery for open radical prostatectomy into one of four treatment groups.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Hamburg, Germany, 20246
- Department of Anesthesiology; Center of Anesthesiology and Intensive Care Medicine, Hamburg Eppendorf University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Radical open abdominal prostatectomy scheduled in the operation theater where the study is conducted
- > 18 years
Exclusion Criteria:
- Chronic opioid therapy
- Beta blocker and digitalis therapy
- Eye disease with affection of pupil reactivity
- Pacemaker therapy
- Higher degrees of cardiac arrhythmias, e.g. atrial fibrillation
- Pre-operative medication with steroids
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PPI (Pain Pupillary Index)
Opioid administration (remifentanil) in intervention group is guided by PPI derived from video-pupillometry performed with the AlgiScan™ by IDMed, Marseille, France.
The device measures the degree of pupillary reflex dilation (PRD) following a nociceptive stimulation.
It automatically increases the intensity of the electric stimulation from 10 to 60 mA and displays the PPI as numerical index between 0 and 10.
A low PPI score indicates deep, a high score light analgesia.
A PPI score of 2-3 is supposed to represent an optimal level of analgesia.
A remifentanil bolus of 30 µg will be administered and the infusion rate of remifentanil will be increased by 0.03 µg/kg/min if PPI score is calculated more than 3. Remifentanil infusion will be decreased by 0.03 µg/kg/min if PPI score is <1.
|
Elective surgery in radical open abdominal prostatectomy.
Opioid titration (remifentanil) is guided by analgesia indices during general anesthesia in the experimental arms.
|
Experimental: SPI (Surgical Pleth Index)
Opioid administration (remifentanil) in intervention group is guided by SPI derived from photoplethysmography performed by the device CARESCAPE™ B650 Patient Monitor by GE Healthcare, Helsinki, Finland.
Included in the monitoring system is a software that continuously calculates the SPI from normalized heart rate and pulse wave amplitude derived from finger plethysmography.
The numerical index ranges between 0 (low sympathetic tone) and 100 (high sympathetic tone).
A SPI score between 20 and 50 has been proposed as the target range.
A remifentanil bolus of 30 µg will be administered and the infusion rate of remifentanil will be increased by 0.03 µg/kg/min if SPI score is calculated more than 50.
Remifentanil infusion will be decreased by 0.03 µg/kg/min if PPI score is calculated below 20.
|
Elective surgery in radical open abdominal prostatectomy.
Opioid titration (remifentanil) is guided by analgesia indices during general anesthesia in the experimental arms.
|
Experimental: NOL (Nociception Level)
Opioid administration (remifentanil) in intervention group is guided by NOL derived from finger photoplethysmography performed with the device PMD200™ manufactured by Medasense, Ramat Gan, Israel.
The device continuously calculates the NOL with a multi-parametric approach from pulse rate, pulse rate variability, pulse wave amplitude, skin conductance level and fluctuations, skin temperature and finger motion.
It is presented on a scale from 0 (no pain) to 100 (extreme pain).
A NOL score between 10 and 25 has been proposed as the target range.
A remifentanil bolus of 30 µg will be administered and the infusion rate will be increased by 0.03 µg/kg/min if NOL score is calculated more than 25.
Remifentanil infusion will be decreased by 0.03 µg/kg/min if PPI score is calculated below 10.
|
Elective surgery in radical open abdominal prostatectomy.
Opioid titration (remifentanil) is guided by analgesia indices during general anesthesia in the experimental arms.
|
Active Comparator: Control
Opioid administration (remifentanil) in control group is guided according to standard clinical practice of the attending anesthesiologist based upon changes of heart rate, blood pressure, lacrimation and sweating of the patient.
|
Elective surgery in radical open abdominal prostatectomy.
Opioid titration (remifentanil) is guided by clinical signs in the control group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intraoperative opioid consumption
Time Frame: 1 day
|
Compares the amount of intraoperative opioid administration (remifentanil) per minute of general anesthesia and per kg bodyweight between groups.
|
1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to extubation
Time Frame: 1 day
|
Postoperative recovery time: Time interval between end of operation and tracheal extubation of the patient.
|
1 day
|
Time to Fit-for-discharge
Time Frame: 1 day
|
Postoperative recovery time: Time interval between postoperative tracheal extubation and the patient reaching fit-for-discharge criteria. criteria from the PACU to the ward. |
1 day
|
Postoperative pain level
Time Frame: 1 day
|
Postoperative pain level measured with the highest score in numeric pain rating scale (NRS).
|
1 day
|
Postoperative opioid administration
Time Frame: 1 day
|
Amount of postoperative opioid administration (piritramid) in the postanesthesia care unit (PACU).
Piritramid is given if NRS score is > 3.
|
1 day
|
Patient satisfaction
Time Frame: 2-21 days
|
Patient satisfaction with the general anesthesia and pain management evaluated by a numeric rating scale.
|
2-21 days
|
Release of stress hormones
Time Frame: 1 day
|
Amount of perioperative plasma level of cortisol and ACTH.
|
1 day
|
Collaborators and Investigators
Investigators
- Principal Investigator: Rainer Nitzschke, MD, Department of Anesthesiology, Hamburg Eppendorf University Medical Center
- Principal Investigator: Sandra Funcke, MD, Department of Anesthesiology, Hamburg Eppendorf University Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20171120
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
susanne beckerSNSFCompletedLow Back Pain | Pain, Acute | Pain, ChronicSwitzerland
Clinical Trials on Opioid administration (remifentanil) in intervention group
-
Universitätsklinikum Hamburg-EppendorfCompletedPain | Pain, Postoperative | Analgesia | Opioid Use | Nociceptive PainGermany
-
University Medical Center GroningenCompletedAnesthesia | Hemodynamic Instability | Interaction | Disorder of Oxygen TransportNetherlands
-
Cukurova UniversityCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Completed
-
Nantes University HospitalCompleted
-
Università degli Studi di FerraraCompletedTest the Differences Between Schinder's TCI Model and MCIItaly
-
Fundacio d'Investigacio en Atencio Primaria Jordi...Institut Català de la Salut; Agència de Salut Pública de Catalunya (ASPCAT); Servei... and other collaboratorsRecruiting
-
University of HelsinkiFinnish Institute for Health and Welfare; Municipality of Sipoo, Health and... and other collaboratorsCompletedHealth Promotion | MultimorbidityFinland
-
Yonsei UniversityCompleted
-
Yeungnam University College of MedicineCompleted